Abstract

Mission

Age-related cognitive impairment and dementia impose an increasing burden on aging Western societies in terms of diminished quality-of-life and high healthcare costs (approximately €3 billion annually in the Netherlands). Memory loss is often regarded by patients as an indication that they may have Alzheimer’s Disease (AD), although in practice it is also a symptom of many far less serious conditions. An important challenge is therefore to differentiate those patients who will not develop dementia (who can thus be comforted) from those who will develop full-blown AD with dementia (for whom healthcare should be provided).

This project aims to develop new instruments with which to make an earlier and more reliable diagnosis of AD during life and create the conditions for an effective evaluation of novel medication therapies for AD patients.

These aims will be achieved by developing the following:
Consortium History

July 2008: Project began

Links/Social Media Feed

Other website
https://www.myctmm.nl/pro1/general/start.asp?i=4&j=1&k=0&p=0&itemid=73&folder=Neurodegenerative%20diseases&title=Learn

Points of Contact

Principal Investigator
M. A. van Buchem

CTMM Program Manager
Henny Bruinewoud

Sponsors & Partners

BAC
Cyclotron
Leids Universitair Centrum
Maastricht University Medical Center
Merck-Sharpe & Dome
Philips Electronics
To-BBB
Universitair Medisch Centrum St. Radbod
Virtual Proteins
VU Medisch Centrum